lyphomed inc said forming new division called ipharm develop full line generic and proprietary ophthalmic pharmaceuticals lyphomed said its initial phase division will produce products exclusively for 200 mln dlr hospital only market company said its next phase ipharm will extend its market include both hospital and hospital customers which estimates valued 800 mln dlrs billion dlrs total ultimately lyphomed said ipharm will concentrate developing new proprietary ophthalmic dosage forms lyphomed said division has already submitted abbreviated new drug applications food and drug administration and will submit several more within next six months lyphomed said division will operate out its melrose park manufacturing facility and will headed ramesh acharya lyphomed vice president and general manager reuter 